other material
confidence high
sentiment neutral
materiality 0.55
Oramed licenses oral insulin (ORMD-0801) to Medicox for South Korea; up to $18M milestones plus 15% royalties
ORAMED PHARMACEUTICALS INC.
- Exclusive 10-year license for ORMD-0801 in South Korea.
- Up to $18M in developmental milestones; $2M already received.
- Up to 15% royalties on gross sales; Medicox funds regulatory approval.
- Medicox also pays transfer price per capsule; distribution targets agreed.